Literature DB >> 28448385

Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial.

Bin Li1,2, Hong Hu1,2, Yawei Zhang1,2, Jie Zhang1,2, Longsheng Miao1,2, Longfei Ma1,2, Xiaoyang Luo1,2, Yiliang Zhang1,2, Ting Ye1,2, Hecheng Li3, Jianhua Zhou4, Yuan Li2,5, Lei Shen2,5, Kuaile Zhao2,6, Min Fan2,6, Zhengfei Zhu2,6, Jialei Wang2,7, Jie Xu1,2, Youjia Deng1,2, Qiong Lu1,2, Huixun Jia2,8, Xinghua Cheng1,2, Hang Li1,2, Yang Zhang1,2, Chenguang Li9, Yunjian Pan1,2, Shilei Liu10, Haichuan Hu1,2, Longlong Shao1,2, Yihua Sun1,2, Jiaqing Xiang1,2, Haiquan Chen1,2.   

Abstract

OBJECTIVE: To investigate whether survival is improved by using the right thoracic approach (extended lymphadenectomy) compared with the left thoracic approach (limited lymphadenectomy) for esophageal cancer.
BACKGROUND: The optimal surgical technique for esophageal cancer remains unclear.
METHODS: Between May 2010 and July 2012, 300 patients with middle and lower thoracic esophageal carcinoma were randomized to receive esophagectomy through either the right or left thoracic approach. Of these, 286 patients with squamous cell carcinoma determined by postoperative pathology were included in this analysis. Disease-free survival (DFS) and overall survival (OS) were compared between the right (n = 146) and left thoracic groups (n = 140).
RESULTS: The median follow-up was 55.9 months [95% confidence interval (CI): 53.1-58.6]. The 3-year DFS rates were 62% and 52% in the right and left thoracic arms, respectively [hazard ratio (HR) 0.709; 95% CI, 0.506-0.995; P = 0.047, log-rank test]. The 3-year OS rates were 74% and 60%, respectively (HR, 0.663; 95% CI, 0.457-0.961; P = 0.029). Subgroup analyses revealed longer DFS in the right thoracic arm (vs left thoracic arm) in patients with lymph node involvement (HR, 0.632; 95% CI, 0.412-0.969, P = 0.034), but not in patients without lymph node involvement (HR, 0.757; 95% CI, 0.434-1.320, P = 0.325), and in patients with R1-2 resection margins (HR, 0.495; 95% CI, 0.290-0.848, P = 0.009), but not R0 margins (HR, 0.944; 95% CI, 0.603-1.477, P = 0.801).
CONCLUSIONS: Compared with the left thoracic approach, the right thoracic approach associated with increased DFS and OS in esophageal squamous cell carcinoma patients, particularly in those with lymph node involvement and/or R1-2 resection margins.

Entities:  

Mesh:

Year:  2018        PMID: 28448385     DOI: 10.1097/SLA.0000000000002280

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  Impact of Examined Lymph Node Count for Esophageal Squamous Cell Carcinoma in Patients who Underwent Right Transthoracic Esophagectomy.

Authors:  Yu-Zhen Zheng; Xiao-Qiang Li; Jun-Ye Wang; Hong Yang; Jing Wen; Wen-Yu Zhai; Lian-Xiong Yuan; Shen-Shen Fu; Hong-Ying Liao; Jian-Hua Fu
Journal:  Ann Surg Oncol       Date:  2020-10-18       Impact factor: 5.344

2.  Comparison of Ivor Lewis and Sweet esophagectomy for middle and lower esophageal squamous cell carcinoma: A systematic review and pooled analysis.

Authors:  Yuhang Xue; Donglai Chen; Wei Wang; Wenjia Wang; Lei Chen; Yonghua Sang; Yongbing Chen; Weihua Xu
Journal:  EClinicalMedicine       Date:  2020-10-10

3.  Comparison of Ivor-Lewis versus Sweet procedure for middle and lower thoracic esophageal squamous cell carcinoma: A STROBE compliant study.

Authors:  Jun Wang; Ning Wei; Nanqing Jiang; Yiming Lu; Xiaoying Zhang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis.

Authors:  Qi Wang; Zixiang Wu; Tianwei Zhan; Shuai Fang; Sai Zhang; Gang Shen; Ming Wu
Journal:  BMC Cancer       Date:  2019-05-27       Impact factor: 4.638

5.  Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501).

Authors:  You-Sheng Mao; Shu-Geng Gao; Yin Li; An-Lin Hao; Jun-Feng Liu; Xiao-Fei Li; Tie-Hua Rong; Jian-Hua Fu; Jian-Qun Ma; Mei-Qing Xu; Ren-Quan Zhang; Gao-Ming Xiao; Xiang-Ning Fu; Ke-Neng Chen; Wei-Min Mao; Yong-Yu Liu; Hong-Xu Liu; Zhi-Rong Zhang; Yan Fang; Dong-Hong Fu; Xu-Dong Wei; Li-Gong Yuan; Shan Muhammad; Wen-Qiang Wei; Philip Wai-Yan Chiu; Shane Lloyd; Francisco Schlottmann; Kenneth Meredith; Jose M Pimiento; Yi-Bo Gao; Jie He
Journal:  Ann Transl Med       Date:  2022-08

6.  Long-term survival of the middle and lower thoracic esophageal cancer patients after surgical treatment through left or right thoracic approach.

Authors:  Ding Yang; You-Sheng Mao; Jie He; Shu-Geng Gao; Ke-Lin Sun; Ju-Wei Mu; Qi Xue; Da-Li Wang; Yu-Shun Gao; Jun Zhao; Xiang-Yang Liu; De-Kang Fang; Jian Li; Yong-Gang Wang; Liang-Ze Zhang; Jin-Feng Huang; Bing Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  Building CT Radiomics Based Nomogram for Preoperative Esophageal Cancer Patients Lymph Node Metastasis Prediction.

Authors:  Chen Shen; Zhenyu Liu; Zhaoqi Wang; Jia Guo; Hongkai Zhang; Yingshu Wang; Jianjun Qin; Hailiang Li; Mengjie Fang; Zhenchao Tang; Yin Li; Jinrong Qu; Jie Tian
Journal:  Transl Oncol       Date:  2018-05-01       Impact factor: 4.243

Review 8.  Recent advancements in esophageal cancer treatment in Japan.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Tomonari Suetsugu; Takeharu Imai; Nobuhisa Matsuhashi; Kazuya Yamaguchi
Journal:  Ann Gastroenterol Surg       Date:  2018-05-28

9.  Comparison of Outcomes Between McKeown and Sweet Esophagectomy in the Elderly Patients for Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.

Authors:  Dongni Chen; Yihuai Hu; Youfang Chen; Jia Hu; Zhesheng Wen
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

10.  Right Compared With Left Thoracic Approach Esophagectomy for Patients With Middle Esophageal Squamous Cell Carcinoma.

Authors:  Yan Zheng; Yin Li; Xianben Liu; Ruixiang Zhang; Haibo Sun; Wenqun Xing
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.